NO20015223D0 - Anvendelse av defektive rekombinante adenovirus inneholdende en nukleinsyre som koder for en angiogenisk faktor for behandlingav pulmon¶r arteriell hypertensjon - Google Patents

Anvendelse av defektive rekombinante adenovirus inneholdende en nukleinsyre som koder for en angiogenisk faktor for behandlingav pulmon¶r arteriell hypertensjon

Info

Publication number
NO20015223D0
NO20015223D0 NO20015223A NO20015223A NO20015223D0 NO 20015223 D0 NO20015223 D0 NO 20015223D0 NO 20015223 A NO20015223 A NO 20015223A NO 20015223 A NO20015223 A NO 20015223A NO 20015223 D0 NO20015223 D0 NO 20015223D0
Authority
NO
Norway
Prior art keywords
treatment
nucleic acid
acid encoding
arterial hypertension
pulmonary arterial
Prior art date
Application number
NO20015223A
Other languages
English (en)
Norwegian (no)
Other versions
NO20015223L (no
Inventor
Serge Adnot
Didier Branellec
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9905272A external-priority patent/FR2792531B1/fr
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of NO20015223L publication Critical patent/NO20015223L/no
Publication of NO20015223D0 publication Critical patent/NO20015223D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
NO20015223A 1999-04-26 2001-10-25 Anvendelse av defektive rekombinante adenovirus inneholdende en nukleinsyre som koder for en angiogenisk faktor for behandlingav pulmon¶r arteriell hypertensjon NO20015223D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9905272A FR2792531B1 (fr) 1999-04-26 1999-04-26 Utilisation d'adenovirus recombinant defectif comprenant un acide nucleique codant pour un facteur angiogenique pour le traitement de l'hypertension arterielle pulmonaire
US13973499P 1999-06-18 1999-06-18
PCT/FR2000/001060 WO2000065043A1 (fr) 1999-04-26 2000-04-21 Utilisation d'adenovirus recombinant defectif comprenant un acide nucleique codant pour un facteur angiogenique pour le traitement de l'hypertension arterielle pulmonaire

Publications (2)

Publication Number Publication Date
NO20015223L NO20015223L (no) 2001-10-25
NO20015223D0 true NO20015223D0 (no) 2001-10-25

Family

ID=26234932

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015223A NO20015223D0 (no) 1999-04-26 2001-10-25 Anvendelse av defektive rekombinante adenovirus inneholdende en nukleinsyre som koder for en angiogenisk faktor for behandlingav pulmon¶r arteriell hypertensjon

Country Status (17)

Country Link
US (1) US20020086004A1 (fr)
EP (1) EP1173564A1 (fr)
JP (1) JP2002543097A (fr)
KR (1) KR20020001846A (fr)
CN (1) CN1376197A (fr)
AU (1) AU782833B2 (fr)
BR (1) BR0010034A (fr)
CA (1) CA2370404A1 (fr)
CZ (1) CZ20013813A3 (fr)
HU (1) HUP0200961A3 (fr)
IL (1) IL145834A0 (fr)
MX (1) MXPA01010849A (fr)
NO (1) NO20015223D0 (fr)
NZ (1) NZ515233A (fr)
PL (1) PL351114A1 (fr)
SI (1) SI20750A (fr)
WO (1) WO2000065043A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020072489A1 (en) * 1998-10-13 2002-06-13 Whitehouse Martha J. Angiogenically effective unit dose of FGF-2 and method of use
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
AU8473401A (en) * 2000-08-04 2002-02-18 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
DE60236646D1 (de) * 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
EP1385862A4 (fr) * 2001-04-13 2005-03-02 Human Genome Sciences Inc Facteur de croissance endoth lial vasculaire 2
US20050232921A1 (en) * 2001-04-13 2005-10-20 Rosen Craig A Vascular endothelial growth factor 2
KR100697321B1 (ko) * 2005-07-27 2007-03-20 박기랑 ＶＥＧＦ－Ａ, ＶＥＧＦ－Ｂ 및 ＶＥＧＦ－Ｃ의 안티센스ｃＤＮＡ를 함유하는 재조합 아데노-연관바이러스（ｒＡＡＶ） 및 이를 함유하는 대장암, 방광암및/또는 폐암 특이적 유전자 치료제
JP5554407B2 (ja) * 2009-06-25 2014-07-23 バイオリーダーズ コーポレーション ポリγ−グルタミン酸−キトサンナノ粒子を含有するアジュバント組成物
CN105833248A (zh) * 2016-04-27 2016-08-10 温州医科大学附属第医院 成纤维细胞生长因子21的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2717495B1 (fr) * 1994-03-18 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, préparation et utilisation en thérapie génique.
AU2051297A (en) * 1996-02-15 1997-09-02 Chiron Corporation Gene therapy method using fgf-5
KR100695590B1 (ko) * 1996-11-01 2007-03-14 아크 테라퓨틱스 리미티드 산화질소 또는 프로스타시클린 생산을 자극하는 약제의 치료학적 용도 및 전달 기구
WO1998037185A2 (fr) * 1997-02-20 1998-08-27 The Board Of Regents Of The University Of Texas System Vecteurs pour expression genique regulee
US6423751B1 (en) * 1998-07-14 2002-07-23 The Brigham And Women's Hospital, Inc. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization

Also Published As

Publication number Publication date
NO20015223L (no) 2001-10-25
CA2370404A1 (fr) 2000-11-02
CZ20013813A3 (cs) 2002-02-13
HUP0200961A2 (hu) 2002-07-29
AU4301700A (en) 2000-11-10
BR0010034A (pt) 2002-01-15
SI20750A (sl) 2002-06-30
EP1173564A1 (fr) 2002-01-23
PL351114A1 (en) 2003-03-24
NZ515233A (en) 2004-08-27
HUP0200961A3 (en) 2004-11-29
KR20020001846A (ko) 2002-01-09
US20020086004A1 (en) 2002-07-04
CN1376197A (zh) 2002-10-23
MXPA01010849A (es) 2002-11-07
WO2000065043A1 (fr) 2000-11-02
IL145834A0 (en) 2002-07-25
JP2002543097A (ja) 2002-12-17
AU782833B2 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
NO20020764L (no) Benzosyrederivater for behandling av diabetes mellitus
NO20015223D0 (no) Anvendelse av defektive rekombinante adenovirus inneholdende en nukleinsyre som koder for en angiogenisk faktor for behandlingav pulmon¶r arteriell hypertensjon
DE60031857D1 (de) Verwendung eines cmp schleifmittels
DE60001692T2 (de) Flüssigkristall-Projektor
DE69801193D1 (de) Verdikte Zusammensetzung enthaltend pyrogene Siliciumdioxid
ATE265210T1 (de) Antihypertriglyceridemische, antihyperglykemische,antiangiogene und wundheilende substituierte indolalkansäure
DK1144368T5 (da) Acetyleniske alfa-aminosyrebaserede sulfonamid-hydroxamsyre-TACE-inhibitorer
DE60025543D1 (de) Flüssigkristall-Projektor
EE200200203A (et) Südame arütmia ravis kasutatavad uued oksabispidiinühendid
DE60042589D1 (de) Flüssigkristallverbindungen
HUP0200638A2 (en) Compounds derived from benzoic acid esters, composition containing said compounds and use thereof
EP1146383A4 (fr) Projecteur a reflexion a cristaux liquides
DE50001690D1 (de) Chirurgisches Cerclageband
ID19967A (id) Pengelola memory untuk decoder mpeg
DE69711407D1 (de) Antrieb für eine winde
NO975537L (no) FremgangsmÕte for mÕling av bunn-reflektivitet
EE9900134A (et) Menetlus bensoehappe puhastamiseks
DE69714568D1 (de) Bestimmungsverfahren für einen Blutfaktor
DE60026644D1 (de) Verwendung von Ferulasäure zur Behandlung von Bluthochdruck
DK1013639T3 (da) Arylcarboxylsyre og tetrazolderivater, som indeholder en carbamoyloxyenhed
FR2792531B1 (fr) Utilisation d'adenovirus recombinant defectif comprenant un acide nucleique codant pour un facteur angiogenique pour le traitement de l'hypertension arterielle pulmonaire
NO963559L (no) Rekombinante adenoviruser som koder for hjerne-avledet naurotrofisk faktor (BDNF)
IT1314120B1 (it) Verricello per imbarcazioni a vela.
NO20015538L (no) Selv-sammenstilte biomolekyl¶re strukturer
FR2791999B1 (fr) Composition destinee a la conservation d'adenovirus recombinants infectieux

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application